Moving targets that drive cancer progression.
Shackleton
Mark
M
Melanoma Research Laboratory and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.
D000818:Animals; D045744:Cell Line, Tumor; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D056466:Histone Demethylases / Q000378:metabolism; D006657:Histones / Q000378:metabolism; D006801:Humans; D056484:Jumonji Domain-Containing Histone Demethylases; D008545:Melanoma / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D009687:Nuclear Proteins / Q000378:metabolism*; D012097:Repressor Proteins / Q000378:metabolism*; D014183:Transplantation, Heterologous
D056572:Histone Deacetylase Inhibitors; D006657:Histones; D009687:Nuclear Proteins; D012097:Repressor Proteins; D056466:Histone Demethylases; D056484:Jumonji Domain-Containing Histone Demethylases; C119611:KDM5B protein, human